John B. Buse

105.2k citations
696 papers · 82.6k · 57 hit papers · h-index 128

Impact in

Papers in

    • Diabetes Treatment and Management 370
    • Diabetes Management and Research 143
    • Diabetes, Cardiovascular Risks, and Lipoproteins 43
    • Diabetes Management and Education 24
    • Chronic Kidney Disease and Diabetes 25

John B. Buse

650 papers receiving 77.5k citations

John B. Buse's Hit Papers

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 2025 · 63 citations
630+2+4Years since publication4008001.2k

Peers

John B. Buse
Comparison fields: 5 of 193
  • Endocrinology, Diabetes and Metabolism 52.8k
  • Pharmaceutical Science 2.6k
  • Nephrology 3.3k
  • Cardiology and Cardiovascular Medicine 4.7k
  • Family Practice 451
Replace Michael Albrecht Nauck with:
Michael Albrecht Nauck Germany
Dianna Josephine Magliano Australia
Bernard Zinman Canada
Melanie Jane Davies United Kingdom
David Richard Matthews United Kingdom
Richard M. Bergenstal United States
Edward J. Boyko United States
William H. Herman United States
Ele Ferrannini Italy
Richard E. Pratley United States
John B. Buse relative to Michael Albrecht Nauck Germany Michael Albrecht Nauck's profile →
Citations per field
00.5×2×4×6×7.3×
Michael Albrecht Nauck · 1×
Citations per year

Countries citing papers authored by John B. Buse

Since Specialization
Citations

This map shows the geographic impact of John B. Buse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B. Buse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B. Buse more than expected).

Fields of papers citing papers by John B. Buse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John B. Buse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B. Buse. The network helps show where John B. Buse may publish in the future.

Co-authors

The 25 scholars most cited alongside John B. Buse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John B. Buse Line = papers co-authored together John B. Buse links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 696 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Hit paper breakdown →
20165824
2
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Hit paper breakdown →
20123386
3
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Hit paper breakdown →
20083150
4
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Hit paper breakdown →
20182947
5
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Hit paper breakdown →
20122788
6
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Hit paper breakdown →
20142552
7
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Hit paper breakdown →
20152091
8
The Metabolic Syndrome: Time for a Critical Appraisal
Hit paper breakdown →
20051943
9
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Hit paper breakdown →
20171724
10
Strategies for Multivessel Revascularization in Patients with Diabetes
Hit paper breakdown →
20121382
11
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Hit paper breakdown →
20091278
12
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Hit paper breakdown →
20221248
13
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Hit paper breakdown →
20181213
14
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
Hit paper breakdown →
20041147
15
Liraglutide and Renal Outcomes in Type 2 Diabetes
Hit paper breakdown →
20171012
16
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Hit paper breakdown →
2006984
17
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Hit paper breakdown →
2019932
18
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Hit paper breakdown →
2008922
19
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Hit paper breakdown →
2006869
20
How Do We Define Cure of Diabetes?
Hit paper breakdown →
2009817

About John B. Buse

John B. Buse is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology, Pharmaceutical Science, Genetics and Infectious Diseases, having authored 696 papers that have together received 82.6k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (370 papers), Diabetes Management and Research (143 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (43 papers), COVID-19 Clinical Research Studies (28 papers), Pancreatic function and diabetes (26 papers), Chronic Kidney Disease and Diabetes (25 papers), Diabetes Management and Education (24 papers) and Genetic Associations and Epidemiology (20 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (52.8k citations), Pharmaceutical Science (2.6k citations), Nephrology (3.3k citations), Cardiology and Cardiovascular Medicine (4.7k citations) and Family Practice (451 citations). John B. Buse has collaborated with scholars based in United States, United Kingdom and Denmark. Frequent co-authors include Richard M. Bergenstal, Ele Ferrannini, Απόστολος Τσάπας, Bernard Zinman, Michael Albrecht Nauck, Anne L. Peters, Rury R. Holman, Michaëla Diamant, Richard C. Wender and David Richard Matthews. Their work appears in journals such as Diabetes Care, Diabetes Obesity and Metabolism, Diabetes, Diabetologia and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact